Prior Acne Predicts Breakouts With JAK Inhibitors in AA
They reviewed demographics, medical history, alopecia history, acne history, current acne, and JAKi use.
The JAKis used were baricitinib (n = 18), deuruxolitinib (n = 17), ritlecitinib (n = 17), upadacitinib (n = 1), and tofacitinib (n = 1). TAKEAWAY: Of all patients, 29 developed acne and 25 did not. Among those with acne, 16 (55%) had mild, nine (31%) had moderate, and four (14%) had severe disease. Overall, 32 (59.3%) patients had a history of acne, including 24 (83%) of the 29 who developed acne during JAKi treatment.
Patients with prior acne history showed a significantly higher likelihood of developing acne during JAKi treatment (odds ratio [OR], 5.95; P = .027). Patients with acne on JAKi were also younger than those without acne (average, 33.6 vs 44.9 years; P = .0097).
= .027). Patients with acne on JAKi were also younger than those without acne (average, 33.6 vs 44.9 years; = .0097). Acne onset typically occurred early in treatment, with 23 (79%) patients developing acne within 3 months; 17 (59%) experienced relapsing/remitting disease. Acne completely resolved in five (17%) patients.
Most patients reported the same (54%) or worse acne severity (29%) after treatment initiation compared with previous acne severity.
Among patients who developed acne, 62% pursued treatment options, with 67% reporting some improvement, while only 3% discontinued JAKi due to acne. IN PRACTICE:
'Younger patients and those with acne history are especially prone to acne on JAKi with similar severity to prior acne,' the study authors wrote. 'Dermatologists should investigate patient acne history prior to JAKi initiation,' they added, and those with a history 'should be counseled on risk of new-onset acne and informed that JAKi-associated acne has moderate responsiveness to conventional therapies.' SOURCE:
The study was led by Emily R. Gordon, Columbia University Vagelos College of Physicians and Surgeons, New York City, and was published online on April 29 in JAAD International . LIMITATIONS:
The study was limited by reliance on patient recall and self-assessment of acne severity. DISCLOSURES:
The authors reported having no funding source or relevant conflict of interests.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Credit
Lead image: E+/Getty Images
Medscape Medical News © 2025 WebMD, LLC
Cite this: Prior Acne Predicts Breakouts With JAK Inhibitors in AA - Medscape - May 12, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
This Advice From Economics Might Be The Answer To Your Parenting Burnout. Here's Why.
When my wife and I brought our first child home from the hospital, we planned on diligently following all of the expert recommendations regarding his care: He would breastfeed exclusively and sleep in a bassinet beside our bed, on his back, in a properly ventilated room. We had read about SIDS and would take every possible precaution. What could be more important that preventing harm from coming to our child? Almost immediately, however, we ran into trouble. Our baby stopped peeing. He was dehydrated and hungry, somehow, although he spent pretty much all day at my breast. So we feed him some infant formula using a medicine dropper, which he lapped up hungrily, sending me into a shame spiral that took months of therapy to crawl out of. But at least with the supplementary formula we were able to keep him happily fed. Related: The second problem sent us into a territory that was even more mortifying. In spite of the fact that my breasts were only partially functional, the baby was extremely attached to them. As in, he would only sleep if they were right there, right beside him, skin to skin with his tiny cheek. Every time he feel asleep while nursing and unlatched his little rosebud lips, I moved as stealthily as possible to try to get him into the bassinet. But more often than not, he woke and started crying. And even if I could get him to lie in the bassinet, it often didn't last long. The end result was that I spent a lot of time nursing him in the chair, and, in my desperation and exhaustion, I often fell asleep. My wife could tell, just by looking at us, that this was not a safe situation. Since it wasn't possible to get him into the bassinet, we just cleared our bed of blankets and pillows and let him sleep where he wanted to, right next to my body. We didn't tell anyone. We had been taught that bed-sharing with a baby was deadly, so we certainly weren't going to admit to doing it. This was all back in 2009, before economist Emily Oster began publishing her bestselling books, in which she brings a unique, data-driven perspective to the art of parenting. In her second book, 'Cribsheet,' she explains how holding up the ideal infant sleeping arrangement as the only permissible option can actually lead parents to put their babies in more danger. Because although it is safest to have baby sleep on a separate surface, it is much more dangerous to sleep with a baby on a sofa or armchair. Sixty-seven times more dangerous. Though it wasn't a best-case scenario that the baby wasn't in the bassinet, he was a lot safer sleeping next to me on the mattress instead of in the recliner. Infant sleep, Oster writes, is one example of a scenario in which we might benefit from considering what she calls 'second best' parenting. It is a term she borrows from economics. 'When we are giving advice in parenting, we tend to be absolutist: There is the best option and then everything else,' Oster told HuffPost, She has used the term 'outer darkness' to refer to everything else — as in, if it's not the best option, it's all equally bad and scary. But this all-or-nothing approach doesn't apply well to infant sleep, where we clearly have a first best option (bassinet/crib in same room as parent) followed by a second best option (on a clear, flat sleeping surface next to the nursing parent) and then, way, way down, the 67th best option of a desperate mother accidentally falling asleep in an armchair while holding the baby because she has been told that under no circumstances should she consider bringing the baby into her bed. 'The idea of 'second best' is to recognize that within the category of 'other options,' some are better than others. The second best is the best option that we can achieve,' Oster said. She thinks that this can be a useful framework for other parenting choices, too, such as what to feed our children. 'We're told the best snack for our kids is, say, a whole apple and a glass of water. But what if your kid doesn't eat that? We don't help people pick well among the options their child will eat. You'd be forgiven for thinking that once you're going to applesauce, you might as well give a pile of cookies. But actually those aren't the same.' Believing that there is only one right way and the rest are wrong sets us up to see only black and white when actually there are so many shades of gray. 'When we tell people that it's the 'best or the rest,' we do not allow for them to choose smartly among the rest,' Oster said. In addition to not choosing well, this thinking makes people feel badly about how they're parenting. 'When we tell people they aren't doing their best, that disempowers them. And no one parents well from a place of shame,' Oster added. Finding Other Good Options Beyond Perfect The advantage of referring to 'second best' is that, with the word 'best,' parents are left with space to take pride in their parenting. A silver or bronze medal is still a win, after all. The argument that Oster is making is similar to that of 'good enough parenting,' an idea popularized in the 1950s by Donald Winnicott. Parenting coach Kristene Geering told HuffPost that this is the framework she uses with parents. 'It's based on the notion that there is no such thing as perfect,' Geering explained. 'Part of being human is that there are challenges, there are times when there's no clear or easy path (which is also how we learn). There is no 'best.' You take what information you have, make a decision based on that and then you learn as you go along.' Geering thinks this dovetails nicely with Carol Dweck's 'growth mindset,' in which as we learn more, we do better. Geering said she often tells families that 'we're all doing the best we can with what we have' and advises, 'Learn from your mistakes, repair as you go, and show your children how to hold compassion for yourself and those around you.' She likes the 'good enough' phrasing because it makes room for the idea that there are many different options that might be 'bests' for different families dealing with different circumstances. Geering agrees with Oster that it's important to move parents out the space of 'all is lost,' where they may get trapped in their shame. She said that where she works in Silicon Valley, 'I see a lot of parents fall into this trap of trying to be 'perfect' ... and then researching themselves into a state where they're almost frozen with indecision.' With an endless amount of information readily available, this isn't an uncommon place for parents to land. 'I've fallen into this trap as well,' Geering admitted. 'Things like which school to attend, which activity to sign up for... it's really overwhelming.' Make Peace With Your 'Good Enough' Using a 'second best' or 'good enough' mindset doesn't come naturally to people raised in a culture of competition. But sooner or later, all parents are faced with a scenario that challenges expectations of perfection. For Geering, a clear example of this in her own family was pandemic schooling. 'I watched my own kids struggle on 'Zoom school,' to the point where it was clear this would never work for them. So I pulled them, and we did homeschool for a year... while my husband and I both worked full time. Was it perfect? Nope. Was it 'second best'? I have no idea.' Her kids are 'still catching up on math,' she said, although they also 'gained a lot of skills in independence.' 'Instead of beating myself up on all the math they missed out on, I looked at it from the point of view that I was doing the best I could in really awful circumstances. And I looked at all the moms in my friend groups and the parents I was working with, and I saw everyone making different decisions, based on their specific circumstances. Absolutely no one did the 'best' thing... because there was no 'best' thing.' Whether you think of it as 'second best' or 'good enough,' parenting within this framework, as opposed to one in which there is only one right option for all families, makes room for you to give yourself some grace. An added benefit of letting go of a perfection-or-nothing mindset is the weight that this takes off of our kids. If we 'show them how to repair the relationship when we mess up and share our learning process with them,' Geering said, 'it lets them be compassionate with themselves, learn from their mistakes, create authentic and meaningful relationships with others, and have a growth mindset as their default throughout life. That's pretty powerful stuff.' Related... Parents Are Lying About Where Their Babies Sleep At Night. Here's Why That's A Problem. What Second-Time Parents Wish They Didn't Stress About The First Time Around This 1 Thing May Be Wearing Parents Out Everywhere
Yahoo
4 minutes ago
- Yahoo
First PRIZM Study Participant Enrolled in Tisento Therapeutics' Open-Label Extension Study in MELAS
Participants Who Complete Treatment in Global Phase 2b PRIZM MELAS Study Are Eligible to Enroll CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Tisento Therapeutics today announced that the first participant has enrolled in the company's open-label extension study in MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes). The extension study (NCT06961344) is evaluating the long-term safety and tolerability of zagociguat in individuals with MELAS who complete treatment in the global Phase 2b PRIZM study, which is expected to complete screening in the next months. The extension study is intended to provide uninterrupted access to zagociguat for clinical trial participants for up to two years and evaluate the long-term safety of zagociguat. 'We're pleased to reach the important milestone of enrolling the first PRIZM study participant into our open-label extension study,' said Peter Hecht, Ph.D., chief executive officer of Tisento. 'Enthusiastic engagement by MELAS patients and physicians is powering momentum in our development program, and we look forward to completing PRIZM enrollment in the next few months.' The PRIZM study is actively enrolling in the U.S., Canada, Australia, United Kingdom, Italy, and Germany, and interested individuals are encouraged to discuss participation with their physician. PRIZM is evaluating the impact of zagociguat treatment on fatigue, cognitive performance, and other key aspects of MELAS. The clinical outcome assessments and endpoint strategy for the PRIZM study were informed by Tisento's interview study in which individuals living with MELAS described the symptoms and impacts of the disease that are most important to them. Participants who complete treatment in PRIZM have the opportunity to enroll in the open-label extension study. About the PRIZM Study PRIZM – a Phase 2b Randomized, Placebo-Controlled Trial Investigating Zagociguat in MELAS – is evaluating the efficacy and safety of oral zagociguat 15 mg or 30 mg compared to placebo when administered once-daily for 12 weeks in participants with genetically and phenotypically defined MELAS. The PRIZM study has a crossover design, with two 12-week treatment periods separated by a 4-week washout period. All participants will receive zagociguat during one of the 12-week periods and placebo during the other. Participants who complete treatment in the study have the opportunity to enroll in an open-label extension study. The global PRIZM study is now enrolling approximately 44 participants at mitochondrial disease centers of excellence in the U.S., Italy, Germany, United Kingdom, Australia, and Canada. For more information, please visit or (NCT06402123). Interested individuals can also reach out to their physicians for participation details. About Zagociguat Zagociguat is a once-daily, oral, clinical-stage investigational medicine with potential to positively impact both peripheral and central nervous system manifestations of mitochondrial diseases. Zagociguat stimulates soluble guanylate cyclase (sGC), an enzyme that is found in virtually every cell in every tissue of the body and is part of a system of cellular mechanisms that control critical physiological functions including neuronal function and blood flow. A first-in-class, brain-penetrant sGC stimulator, zagociguat is hypothesized to rebalance dysregulated cellular pathways in MELAS. By restoring cellular functions that support mitochondria, zagociguat may help restore mitochondrial energy production and physiological function. In a Phase 2a study in patients with MELAS, zagociguat exhibited a favorable safety profile, exposure throughout the body including in the central nervous system, and improvements in neuronal function, mitochondrial function, and blood flow in the brain. Zagociguat is currently being evaluated as a treatment for MELAS in the Phase 2b PRIZM study. Zagociguat received Fast Track designation from the U.S. Food and Drug Administration for the treatment of MELAS. Fast Track is a process designed to facilitate the development and potentially expedite the review of medicines to treat serious conditions and fill an unmet medical need, with the goal of getting important new drugs to patients earlier. For more information, visit About Tisento Therapeutics Tisento Therapeutics, a privately held biotech company, is developing novel medicines to treat diseases with significant unmet need, beginning with MELAS and other genetic mitochondrial diseases. Ti sento means 'I hear you' in Italian; our approach to innovation begins with listening to patients and then channeling what we learn into decisive actions that shape our research and clinical programs. Tisento is guided by a high-caliber internal team of biopharma veterans and an extensive external network of expert physicians, patient advocacy groups, researchers, industry-leading vendors, and other close collaborators who are partners in our mission to develop meaningful treatments for mitochondrial diseases. Learn more at our website, or connect with us on LinkedIn, Facebook, X (@tisentotx), or Bluesky. Contact Tisento Media RelationsJessi Rennekamp, Astrior CommunicationsEmail: jessi@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
6 minutes ago
- Forbes
NYU Partners With Apa Aesthetic To Propel The Education Of Aesthetic Dentistry
The NYU College of Dentistry has partnered with Dr. Apa to launch an aesthetic dentistry fellowship and training program. Dr. Apa is the recognized leader in aesthetic dentistry and the pioneer of Facial Aesthetic Design. Instead of focusing only on the smile (or worse, taking a "single-tooth-dentistry" approach), he looks at the entire face: how the teeth support the lips, the balance of the jawline, and how the smile fits each person's unique features. Known for designing teeth that don't just look good in the mouth but elevate the whole face, bringing harmony, youthfulness, and confidence back to the person. Aesthetic dentistry, despite its complexity and impact, is not recognized as a formal dental specialty by the American Dental Association (ADA). This means there are no standardized education requirements, board certifications, or regulatory oversight specific to aesthetic work, unlike specialties such as orthodontics or periodontics. As a result, any general dentist can promote themselves as an "aesthetic" or "cosmetic" dentist without advanced training in facial proportions, occlusion, material science, or minimally invasive techniques. This lack of formal distinction creates confusion for patients and contributes to inconsistent outcomes across the industry. Dr. Apa has long argued that aesthetic dentistry deserves specialty status, not just to elevate the standard of care, but to protect patients and establish a new level of clinical, artistic, and ethical excellence. More than 60% of Dr. Apa's cases are redos, correcting work done elsewhere. Sometimes the problem is form (think: aesthetics), other times it is function (think: headaches, no bite), and most times it's a combination of the two. This partnership with NYU's College of Dentistry is the first step in making aesthetic dentistry a specialty not just an afterthought. 'There are two distinct programs in my name at NYU, and they serve different stages in a dentist's journey, but both are about creating access to excellence. The Apa Honors Program in Aesthetic Dentistry is for standout D4 students who already show real potential. It's selective, not just based on grades, but on mindset, talent, and vision. Once accepted, they're brought into a curated training experience where they're exposed to the artistry, protocols, and decision-making behind great aesthetic dentistry. There's a competitive application and interview process and only about 10 students make the cut,' Dr Apa explained. 'Then there's the Apa Advanced Clinical Fellowship, which is for licensed dentists, both U.S. and international, who are ready to go deeper. It's a full-time, one-year immersion that's as close as you can get to how we operate in private practice. These fellows are treating real aesthetic cases, using protocols that mirror what we do at Apa Aesthetic and learning the details that separate 'good enough' from truly transformative. We choose people who are hungry, who want to master this and carry it forward in their careers. Success in aesthetic dentistry isn't just about clinical skill; it's about mindset, discipline, and how you carry yourself. You can be the most technically gifted dentist in the room, but if you don't show up with presence, confidence, and the ability to evolve, you'll never lead in this space. I worked closely with NYU to design the Apa Suite to reflect more than just function; it delivers an the room layout to the in-house lab to the integration of L'Atelier Forte, everything is intentional. Even the right jacket can change how a patient sees you, and how you see yourself. I want the students to feel that – to understand that what we do is as much about who you are as how you transform a smile.' One of the most unique features of the partnership is the Apa Suite at the NYU campus. It will serve not only as an educational space but will also give accessibility for patients to high-level aesthetic dentistry. 'I wanted to build a bridge. For patients, that means opening the door to high-level aesthetic care at more accessible pricing. For students, it means bringing them into the philosophy and precision of cosmetic dentistry earlier in their education and careers. We're setting a new standard and making sure it's built to last,' Dr. Apa added. Patients can expect the full spectrum of what is typically offered at Apa Aesthetic but delivered in an academic setting with exceptional oversight. That means everything from teeth whitening to fillings and full smile makeovers. The Apa Aesthetic Suite offers students a clinical training environment that replicates the look, feel, and pace of a high-end private practice with the added value of real-time mentorship and expert supervision from world-class faculty. Among its most distinctive features is our fully integrated, in-house ceramic lab. Here, a master ceramist works directly alongside students, designing and fabricating custom restorations in real time. This immersive, collaborative approach bridges the gap between clinical dentistry and laboratory artistry, a level of integration rarely seen in academic institutions. Students are not only learning the techniques of modern aesthetic dentistry, they are living it For NYU, partnering with Dr. Apa on these initiatives was a no-brainer. As an alumn of NYU, Dr Apa maintained a connection to NYU as a lecturer and mentor to dental students over the years. When NYU was looking to transform its educational dentistry, Dr. Apa was the perfect fit for the endeavor. 'What began as a discussion about creating a permanent home for students in the Aesthetics Honors Program grew into a more comprehensive plan to enhance aesthetic dentistry education and design a state-of-the-art aesthetics suite with an elevated patient experience in mind. Together, we share a commitment to innovation and academic excellence. The collaborative effort of conceptualizing and designing a facility that reflects the future of aesthetic dentistry has been a transformative experience for me, professionally, and I couldn't be more pleased with the result. The Apa Aesthetic Suite at NYU Dentistry stands as a model for aesthetic dentistry education, providing our students with the tools, mentorship, and environment to emerge as thoughtful, highly skilled, and globally aware practitioners, while also providing our patients with leading-edge aesthetic treatments that enhance their health, confidence, and overall well-being,' shared Dr. Anabella Oquendo, Director for the Apa Advanced Clinical Fellowship in Aesthetic Dentistry at NYU. 'What we have created is a transformative ecosystem that simply does not exist elsewhere. It is an incubator for the next generation of aesthetic leaders, where dentistry meets design, art meets science, and talent meets purpose. And at its core is a belief in giving back, lifting others, and building the future of our profession.' Dr. Clement Kairouz, Associate at Apa Aesthetic New York and Professor at NYU, sees the integration of cosmetic principles early in education as equipping future dentists with the vision and precision to meet modern expectations and elevate the standard of care. 'The future of dentistry is not just healthy; it's beautiful. Now, NYU's next generation of dentists will be better trained to execute on that reality.' Applications are now open for the 2026 Advanced Clinical Fellowship and patients can book services for the Apa Suite online.
